Lawrence Blatt

CIK: 0001242110

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

ALGS

Aligos Therapeutics, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (4 total)

ALGS
Aligos Therapeutics, Inc.
Mar 9, 2026
Award(A)
Stock Option (Right to Buy)
Direct
105.8K shares-
ALGS
Aligos Therapeutics, Inc.
Jul 16, 2025
Award(A)
Stock Option (Right to Buy)
Direct
179.8K shares-
ALGS
Aligos Therapeutics, Inc.
Feb 28, 2025
Award(A)
Stock Option (Right to Buy)
Direct
140.1K shares-
ALGS
Aligos Therapeutics, Inc.
Sep 4, 2024
Award(A)
Stock Option (Right to Buy)
Direct
33.9K shares-

		Type	Shares	Price		Ownership
Mar 9, 2026	ALGS Aligos Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	105,840	-	-	Direct
Jul 16, 2025	ALGS Aligos Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	179,800	-	-	Direct
Feb 28, 2025	ALGS Aligos Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	140,103	-	-	Direct
Sep 4, 2024	ALGS Aligos Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	33,920	-	-	Direct

1-4 of 4 transactions

About BLATT LAWRENCE

BLATT LAWRENCE (SEC CIK 0001242110) files insider reports with the SEC as President and CEO of Aligos Therapeutics, Inc. (ALGS).

Signal8 holds 4 ownership filings by BLATT LAWRENCE, all Form 4s, filed between Sep 6, 2024 and Mar 11, 2026. Those filings report 4 transactions, from Sep 4, 2024 to Mar 9, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on BLATT LAWRENCE's filings is in SOUTH SAN FRANCISCO, CA.

Recent filings by BLATT LAWRENCE

Mar 9, 2026: Grant or award of ALGS derivative securities (Form 4, code A).
Jul 16, 2025: Grant or award of ALGS derivative securities (Form 4, code A).
Feb 28, 2025: Grant or award of ALGS derivative securities (Form 4, code A).
Sep 4, 2024: Grant or award of ALGS derivative securities (Form 4, code A).

Other insiders filing for Aligos Therapeutics, Inc. (ALGS)

Preston Heather, Director
Chavez Margarita, Director
Martell Bridget A, Director
Scopa James Paul, Director
Nuechterlein Carole, Director
Hirth Peter, Director

How to read Form 4 transaction codes